Lifeline begins First Warning trials

Article

Breast cancer detection firm Lifeline BioTechnologies announced last month that it has received clearance to proceed with a 1200-women clinical trial for the company’s work-in-progress First Warning system.The multicenter study will be conducted in

Breast cancer detection firm Lifeline BioTechnologies announced last month that it has received clearance to proceed with a 1200-women clinical trial for the company’s work-in-progress First Warning system.

The multicenter study will be conducted in Buenos Aires and La Plata, Argentina, under the guidance of Dr. Martin Laguens. Lifeline selected the sites because of the large number of unscreened female patients available for study through government medical programs. The three-part protocol will include women referred to breast clinics for existing problems, women recommended for surgical biopsy, and women who have never been screened.

Reno, NV-based Lifeline is developing First Warning as an early-detection, nonimaging breast cancer system for women considered too young for x-ray mammography. The system measures minute temperature changes in breast tissue over a 24 to 36-hour period with leads attached to the skin and a monitor that records data (SCAN 10/28/98). Lifeline hopes to file an application with the Food and Drug Administration next year for use of the product in detecting breast cancer, according to the company.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
Reducing Mammography Workload by Nearly 40 Percent? What a New Hybrid AI Study Reveals
 What New Research Reveals About Portable Low-Field MRI and Patients with Suspected Alzheimer’s Disease
Diagnostic Imaging's Weekly Scan: August 11 — August 17 (Video Version)
© 2025 MJH Life Sciences

All rights reserved.